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T-cell vaccination may prevent or treat cancer and infectious diseases, but further progress is required to increase clinical eﬃcacy.
Step-by-step improvements of T-cell vaccination in phase I/II clinical studies combined with very detailed analysis of T-cell
responses at the single cell level are the strategy of choice for the identification of the most promising vaccine candidates for testing
in subsequent large-scale phase III clinical trials. Major aims are to fully identify the most eﬃcient T-cells in anticancer therapy,
to characterize their TCRs, and to pinpoint the mechanisms of T-cell recruitment and function in well-defined clinical situations.
Here we discuss novel strategies for the assessment of human T-cell responses, revealing in part unprecedented insight into T-
cell biology and novel structural principles that govern TCR-pMHC recognition. Together, the described approaches advance our
knowledge of T-cell mediated-protection from human diseases.
1. Introduction
Despite major advancements in the fields of molecular and
cellular biology, and the improved understanding of cancer
formation and progression, the surgical removal of tumors
remains the most eﬀective therapeutic strategy against can-
cer. While radiation therapy and chemotoxic drugs are often
employed to successfully prolong the disease-free survival
or to slow down tumor progression, their limited specificity
in targeting neoplastic cells is often responsible for a wide
spectrum of common clinical side eﬀects. In this respect,
immunotherapy is a promising therapeutic alternative to
avoid such side eﬀects by activating the patient’s own
immune system against tumor cells. In this Paper we focused
on selected aspects of current vaccination strategies against
melanoma, as well as new and sophisticated tools employed
by immunologists to analyze cellular immune responses by
“zooming in” on single tumor-specific lymphocytes.
1.1. Melanoma. Melanoma arises from the pigment-
producing melanocytes. It is the major cause of mortality
among skin malignancies. The incidence is steadily
increasing at rates over 3% per year, with many hundreds
of new cases per 100 000 inhabitants, and mortality rates
ranging from 0.1 to >10% [1]. These figures, however,
diﬀer largely depending on risk factors such as sun exposure
depending on the local climate. Melanoma is one of the most
antigenic and immunogenic cancers with a high percentage
of tumors expressing well-characterized tumor-associated
antigens. Immunotherapy targeting one or several of these
tumor-expressed antigens has shown promising results over
the past years in enhancing antitumor immune responses.
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It is now well established that spontaneous tumor antigen-
specific T-cell responses are generated in melanoma patients
that can be detected both in the circulation as well as at the
tumor sites. While spontaneous T-cell responses have been
reported against cancer-germline antigens encoded by the
MAGE family, and against NY-ESO-1, T-cell frequencies are
generally very low (10−7 to 10−4) [2]. An exception to this is
the natural immune response observed in most melanoma
patients against the Melan-A/MART1 diﬀerentiation antigen
presented in the context of the MHC class I molecule
HLA-A2. In untreated patients, frequencies of T-cells
specific for this antigen usually range from 0.01% to 0.1%
of total circulating CD8pos cells [3, 4]. These frequencies
are often much higher in metastatic lymph nodes and other
metastases of melanoma patients [5, 6]. In fact unusually
high frequencies (10−3 to 10−4) of A2/Melan-A-specific T
lymphocytes are already found in the blood of newborns
and healthy A2+ individuals. This population of self-peptide
specific T-cells is preferentially selected in the thymus,
presumably due to cross reactivity to unknown self-peptides.
Consequently, large numbers of such cells are released from
the thymus into the periphery as mature, naive precursor
T-cells [7, 8]. Thus, the activation and expansion of this
population of Melan-A-specific CD8 T lymphocytes to
induce clinically relevant tumor cell lysis represents an
important target of immunotherapy.
1.2. Therapeutic Immunization Strategies. The aim of an
eﬃcient cancer vaccine is to activate de novo the immune
system against tumor cells and/or to enhance the preexisting
tumor-specific response. An ideal vaccine would induce
expansion of large populations of cytotoxic T-cells, with
potent antitumor eﬀector functions, both at the tumor-site
but also as a systemic immune surveillance for long periods
of time. The choice of adjuvants and antigenic peptides
used, their combination, and timing are important factors.
Currently there are three major approaches of immunother-
apy: antigen-based vaccines, adoptive cell transfer of eﬃcient
antitumor T-cells, and stimulation of the immune system in
an antigen-nonspecific manner.
Optimal vaccines consist of live or attenuated microbes.
However, for many infectious diseases, and for cancers in
general, such vaccines are not available. Therefore, synthetic
vaccines are developed generally following the rational-
based microbe-induced immune mechanisms. Synthetic
vaccines are composed of at least two basic components:
antigen and adjuvant. The rational of using antigens for
cancer immunotherapy is based on the relatively large
consensus that immune protection against malignant dis-
ease requires antigen-specific (adaptive) immune responses
including T-cells. Some experts argue that stimulation of the
innate immune system alone may be suﬃcient to generate
tumor-specific immunity, since cancer tissue often produces
tumor antigens allowing some activation of antigen-specific
immune responses. Therefore, an increasing number of
novel immune therapies are developed without taking
advantage of (synthetic or recombinant) tumor antigens,
essentially because this approach simplifies drug production
and application. However, tumor cells produce only low
amounts of antigen, which is often not present at the optimal
location and/or time. Therefore, immune responses triggered
by naturally expressed antigens are not suﬃciently timed,
neither strong nor anatomically focused to protect from
tumor progression. In addition, immunotherapy without
antigen often requires high and in part toxic drug doses, in
contrast to vaccines containing synthetic antigens that can
have powerful biological eﬀects even at low doses. For these
reasons we propose that synthetic cancer vaccines should
include tumor antigens.
Besides antigen, the second essential vaccine compo-
nent is the so-called immunological “adjuvant.” Adju-
vants are immune stimulating agents, which are important
because immune responses remain poor when antigens are
administered alone. For many years, adjuvants have been
developed empirically, without significant progress in the
understanding of their molecular nature and mechanisms
of action. The discovery of dendritic cells (DCs) and of
their central role in linking innate with adaptive immune
responses was key for progress. Besides regulating central
mechanisms of the innate immune system, DCs are the
most eﬀective antigen-presenting cells for enabling antigen-
specific T- and B-cell responses. But how are they put in
action? Only about 15 years ago it was discovered that DCs
become activated due to triggering of pathogen recognition
receptors (PRRs). These receptors enable the innate immune
system to sense microbes. The best-characterized families of
PRRs are the Toll-like receptors (TLRs) that bind microbial
products [9–12]. Drugs that stimulate TLRs are promising
adjuvants, particularly CpGs that bind to TLR9. CpGs are
oligonucleotides containing CpG motifs similar to those
observed in bacterial DNA. Our group has shown that
vaccination with emulsions with IFA (Incomplete Freund’s
Adjuvant), containing antigenic peptides and CpG, rapidly
induces strong human CD8pos T-cell responses (0.5%–8%
of circulating CD8pos T-cells) in melanoma patients [13].
Moreover, it is the first synthetic vaccine formulation to
consistently induce ex vivo detectable T-cell responses even
when using a natural tumor peptide, that is, the natural
Melan-A/MART-1 sequence [14].
A novel concept of lymphodepletion was recently intro-
duced in the field of immunotherapy, with the aim of making
“immunological space” and freeing up access to cytokines
such as IL-7 and IL-15 for the tumor-specific T-cells to opti-
mally expand. The rational for this is based on observations
made from viral systems indicating that protective immune
responses require large frequencies of antigen-specific T-
cells. Recently, Rosenberg and colleagues [15, 16] have shown
promising results with adoptive cell transfer of autologous
melanoma-specific T-cells, combined with high-dose IL-
2, in late stage melanoma patients, following transient
lymphodepleting chemotherapy regimen. Although highly
successful (objective antitumor response of 50% for stage
IV melanoma), such a treatment is not easily available
for a large number of patients, due to the requirement
of highly specialized laboratories to support the delicate
procedures of isolation and in vitro expansion of autologous
T-cells, and the intensive care units necessary for the clinical
management of the side eﬀects caused by high-dose IL-2.
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1.3. Insight into the Eﬃciency of a Vaccine Requires Detailed
Analysis of the Immune Response. An increase in the number
and frequency of antigen-specific T lymphocytes is often
observed following peptide vaccination alone, thus achieving
the first aim of candidate cancer vaccines. Unfortunately, the
majority of these patients still experience tumor progression,
despite increased numbers of tumor-specific T lymphocytes.
It is believed that in the small number of patients showing
disease stabilization or even tumor regression following
immunotherapy, tumor-specific T-cells may succeed in
infiltrating tumor tissue, destroying some of the tumor
cells and temporarily reversing the local immunosuppressive
environment. They would thus act like a spark for the
activation, proliferation, and antitumor eﬀector function of
already infiltrated or newly activated tumor-specific T-cells.
It can thus be implied that a successful vaccine may not
solely depend on the induction of large numbers of tumor-
specific T lymphocytes but rather on the activation of a pop-
ulation of eﬀector T-cells with potent antitumor activities
and resistance to the local immunosuppressive environment
(reviewed in [2]). In order to improve the clinical eﬃcacy of
such vaccines, a better characterization of the tumor-specific
immune responses is required. Specifically each vaccine-
induced immune response should be analyzed in terms of
phenotype, function, selection of specific T-cells from the
repertoire, and their aﬃnity/avidity for the MHC-peptide
complex. Importantly, one also needs to examine the changes
and the degree of stability of these parameters over time
and following repeated rounds of vaccination. Furthermore,
a better understanding of the mechanisms that allow long-
lasting memory T-cell survival and of strategies to increase
T-cell migration and eﬀector functions at the tumor site is
needed.
1.4. Cancer versus Infection Models. From an immunological
perspective, tumors can be compared with persistent viral
infections, since in both situations T-cells may successfully
protect from disease. The constant presence of antigen
stimulates the immune system by continuously trigger-
ing antigen-specific T-cells. The major diﬀerence between
cancer and infection is that, in the latter, the immune
response is highly eﬃcient in controlling the virus and
in providing long-lasting protection. Contrarily, antitumor
responses show less robustness compared with antiviral
responses. Some of the explanations for this may be (i)
immune tolerance against self-antigens, (ii) local immune
suppression induced by tumors, and (iii) tumor escape
mechanisms which render the existing immune responses
less eﬃcient. Nevertheless, chronic infections with geneti-
cally stable viruses such as Epstein-Barr virus (EBV) and
cytomegalovirus (CMV) provide useful model situations for
studying the generation and maintenance of highly eﬃcient
T-cell memory responses and for identification of T-cell
correlates of protection in humans.
We divided this paper into six sections, each describing a
particular aspect of current methodological approaches and
technical tools used to dissect antigen-specific CD8 T-cell
responses. Our strategy combining both ex vivo and in vitro
analyses, and utilizing molecular and cellular approaches is
schematically depicted in Figure 1. Each major component
of this outline corresponds to one section of the text, thus
providing a guideline for the reader throughout this paper.
The observed similarities and diﬀerences between viral- and
tumor-specific T-cell responses will be discussed, since they
not only reveal the progress of novel vaccine formulations
against cancers like melanoma, but also the obstacles which
need to be overcome in order to further improve clinical
eﬃcacy.
2. Multiparameter Flow Cytometry Analysis of
Antigen-Primed T Lymphocytes
The development of designed fluorescent peptide/MHC
multimers (formerly called tetramers), which bind stably
to specific TCR molecules on the surface of T-cells [5,
17], has revolutionized the detection of viral- and tumor-
specific T-cells. This approach makes it possible to directly
carry out subset analysis at the antigen-specific T-cell level
ex vivo without preliminary in vitro rounds of antigen
stimulation (reviewed in [18]). Multimer technology com-
bined with multiparametric flow cytometry analysis has
allowed gaining a better understanding of the T-cell specific
immune responses against viruses and tumors. Furthermore,
the ex vivo analysis of antigen-specific populations can
be accompanied by the isolation of T-cell populations of
interest, as well as the use of peptide-MHC multimers as
a stimulus in in vitro functional assays. Briefly, PBMCs
from vaccinated melanoma patients are first enriched for
CD8pos T lymphocytes using anti-CD8-coated magnetic
microbeads. Alternatively, T lymphocytes can be extracted
from resected metastatic lymph nodes (TILNs) or distant
soft/visceral metastases (TILs) [19]. Purified CD8 T-cells
are then incubated using PE-labeled HLA-A∗0201/peptide
multimers [5, 17], in combination with fluorescent antibod-
ies (i) for extracellular diﬀerentiation markers (e.g., CCR7,
CD45RA, CD28, CD27), (ii) for cytolytic molecules (e.g.,
perforin, granzyme B), and/or (iii) for cytokines (IFNγ,
TNFα) (Figure 1).
2.1. Defining Human CD8 T Lymphocyte Subpopulations.
Major eﬀorts have been made in recent years to understand
the relationship between diﬀerent T-cell subpopulations. An
important task has been to define molecular markers that
readily identify and isolate T-cells sharing discrete stages of
cell diﬀerentiation. Circulating naive T lymphocytes form a
relatively homogenous population expressing a well-defined
set of surface glycoproteins and are characterized by the
null expression of eﬀector mediators (e.g., IFN-γ, TNF-
α, granzyme B, perforin, FAS/CD95) and by proliferative
potential (e.g., long telomeres, high detectable levels of
TREC copies). During the past decades, primed antigen-
experienced T lymphocytes have mostly been classified into
two distinct subsets, for example, eﬀector and memory cells
[20]. Eﬀectors are presumably rather short-lived, produce
cytolytic eﬀector molecules, and are capable of migrating
to the site of infection and of killing target cells directly ex
vivo. In contrast, memory cells are long lived, persist after
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Figure 1: Cellular and molecular approaches for the characterization of cytotoxic T-cells following therapeutic vaccination. Each step (1 to
6) in the strategy bears the same name and section number as described in the body of text. (1) Patients undergoing therapeutic vaccination
are monitored closely throughout the clinical study, and blood and tissue samples are collected at numerous time points. (2) Antigen-specific
CD8 T-cell populations are first visualized by the use of fluorescent peptide-MHC multimers then analyzed for their phenotype and subset
composition using multiparameter flow cytometry. T-cell populations of interest can subsequently be isolated for further in vitro [3, 5] or
ex vivo [4, 5] studies. (3) In vitro generated T-cell clones can be subjected to a series of assays to determine their functionality, including
target cell lysis (51C release assay) and cytokine production (ELISpot). (4) Ex vivo sorted single cells are lysed and cDNA purified for gene-
expression and TCR repertoire analysis. (5) Single cell samples or individual T-cell clones can be subjected to spectratyping, for the study of
TCR repertoire diversity, selection, and clonotype composition. The unique signature of each T-cell can be identified, and its frequency
determined. Furthermore, individual T-cell clonotypes can be followed across diﬀerent T-cell compartments, and over time following
therapeutic vaccination. (6) Conclusions drawn from this complete analysis of phenotype and functionality of vaccine-induced immune
responses in melanoma patients can be taken back to the bedside. These results can be translated into improved therapeutic vaccination
regimens aiming for more powerful immune activation and more eﬃcient and specific antitumor responses.
pathogen clearance, and have increased survival properties
and cell division capacities (reviewed in [21]). In line with
this concept, human CD8 T-cells have been delineated with
the help of two cell surface markers, the high isoform of the
common lymphocyte antigen CD45RA and the chemokine
receptor CCR7, and based on their anatomical location
[22–24]. Central memory (TCM) T-cells are characterized
by the ability to repeatedly circulate into lymph nodes
and eventually encounter antigen presented by incoming
CCR7pos mature dendritic cells, in contrast to eﬀector
memory (TEM) cells which downregulate CCR7 and appear
specialized in migrating to peripheral nonlymphoid tissues.
Although this two-marker procedure to identify func-
tionally distinct CD8 T-cell subsets has proven popular, the
recent technical improvements in the ability to dissect the
immune response usingmultiparameter flow cytometry have
indicated the existence of highly heterogeneous antigen-
primed CD8 T subpopulations [25–38]. Importantly, the
term of “eﬀector” and “memory” CD8poscell may only apply
for situations of acute and resolved infections after which
the pathogen is cleared from the host, and not in situations
of persistent latent or chronic active infections where it
becomes more diﬃcult to use this simplified view of defining
primed T-cells (reviewed in [39, 40]). Indeed, in recent years,
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a variety of other phenotypical and functional markers have
been added allowing at present the discrimination of a wide
spectrum of antigen-experienced CD8 T-cells with diﬀerent
phenotypes, functions, and half-lives and that may account
for the heterogeneity of “memory” and “eﬀector” cells
observed following persistent chronic infections (reviewed in
[40, 41]).
2.2. Phenotype of Tumor Antigen-Specific T-Cells follow-
ing Therapeutic Vaccination. Since the fast advancing flow
cytometry technology allows us to analyze as many as 20
fluorochromes simultaneously using 7 lasers, the diﬃcult
task now becomes the choice of the appropriate extracel-
lular and intracellular markers, which would be the most
informative in terms of the phenotypic and functional
characteristics. Therefore, our own strategy of monitoring
antitumor T-cell responses following peptide vaccination of
melanoma patients relies on studies that we perform using
well-established surface markers that allow to best correlate a
particular phenotype of a T-cell with its function in vivo.
First, we uncovered additional heterogeneity among
eﬀector memory and eﬀector CD8 T-cell subsets by study-
ing the functional attributes of such T-cells distinguished
on the basis of expression of the costimulatory recep-
tors CD27 and CD28 [32, 34, 42]. Our studies show
that these subsets can be subdivided into early diﬀerenti-
ated (CCR7−CD45RA−CD27+CD28+) or late diﬀerentiated
(CCR7−CD45RA+/−CD27+/−CD28−) T-cells. Early diﬀeren-
tiated cells express low levels of eﬀector mediators such as
granzyme B and perforin and high levels of CD127/IL-7Rα,
have a relatively short replicative history (long telomeres,
detectable copies of TRECs), and display strong ex vivo
telomerase activity. Therefore, these cells are closely related
to central memory T-cells (CCR7+CD45RA−CD27+CD28+).
Conversely, late diﬀerentiated cells have undergone addi-
tional rounds of in vivo cell division and share eﬀector-type
properties with increased expression of eﬀector mediators
and strong ex vivo cytolytic activity (Figure 2). In line with
these data, our group more recently reported on the detailed
analysis of CD8 T-cell responses specific for EBV and CMV
viruses [43]. During chronic infection with EBV and CMV,
CD8pos T-cell responses to A2/GLC and A2/NLV antigens,
respectively, are composed of heterogeneous populations of
T-cells of various diﬀerentiation stages, with EBV-specific
responses being less diﬀerentiated than CMV-specific ones
[25–38]. Although the sizes/proportions of these subsets
varied between EBV and CMV responses, our recent obser-
vations revealed that all subsets, from early diﬀerentiated to
late diﬀerentiated stages, were found in both viral-specific
responses [43]. Remarkably, this finding was also observed
for CD8 T-cells specific for the influenza matrix protein
peptide (Flu-MA), where up to 20% of these cells were
composed of eﬀector T-cells, alongside the predominant
memory cells [44].
Over the past decade, our group performed extensive
work on antitumor responses against melanoma expressed
antigens before as well as upon peptide vaccination [3, 13,
45–52], and we showed that vaccination is often found
to increase the number of tumor antigen-specific T-cells
and to induce their cell diﬀerentiation. Phenotypic analysis
of Melan-A/MART-1 specific T-cells in vaccinated patients
showed similarities to that of virus-specific (EBV and CMV)
T-cells, in that they were comprised primarily of eﬀector
memory (TEM or EM) cells containing both early (EM
CD28+ defined as EM28pos) and late diﬀerentiated (EM
CD28− defined as EM28neg) T-cells. Compared with the
viral system where we observed almost identical phenotypes
among individuals (i.e., proportions of EM28+ and EM28−
for EBV-specific T-cells), the overall phenotype of Melan-
A/MART-1 specific T-cells, specifically the proportion of
EM28pos versus EM28neg T-cells, seems to be more variable
and to depend on each patient and his/her vaccination
history. Nevertheless, peptide vaccination has been shown to
drive the Melan-A/MART-1 response towards cell diﬀeren-
tiation with progressive upregulation of eﬀector mediators
and cytolytic activity. From this point of view, current
vaccination strategies emerge as progressively successful in
inducing tumor-specific T-cells at high frequencies and with
similar phenotypic and functional characteristics as those
associated with long-lasting protective responses (Rufer,
Speiser, et al., unpublished observations).
2.3. Model of CD8 T-Cell Diﬀerentiation. Altogether, these
in-depth analyses [32, 34, 45, 48] are in agreement with a
model according to which there is a diﬀerentiation pathway
with the stepwise loss of homing (CCR7), costimulatory
(CD27, CD28), and cytokine (IL-7Rα) receptors, as well as
concomitant upregulation of molecules involved in cell-cell
adhesion and target cell destruction (Figure 2). Importantly,
influenza-, EBV-, and CMV-specific T-cells follow the same
pathway of cell diﬀerentiation, although CMV-specific cells
are more frequently late diﬀerentiated than influenza- and
EBV-specific cells [43, 44].
The pathway of T-cell diﬀerentiation described here
(Figure 2) appears also to apply to self-/tumor-specific T-
cells such as Melan-A/MART-1 and NY-ESO-1 in melanoma
patients [45, 48], aside from being found in T-cells specific
for persistent viruses [29, 43], in T-cells responding to acute
viral infections like influenza [44], and in other types of
T-cells (γδpos, CD4pos) [53]. Essentially, following antigen
stimulation, less diﬀerentiated cells like naive and central
memory T-cells expressing CCR7 would initially diﬀerentiate
into eﬀector memory cells, then ultimately into highly
diﬀerentiated eﬀector type of cells (Figure 2). Sallusto and
colleagues suggested that this diﬀerentiation process will
depend upon the signal-strength of interaction between
the T-cell and the antigen-presenting cell during the initial
priming and expansion phase, specifically on factors such
as the aﬃnity of the TCR-MHC-peptide interaction, the
concentration of antigen, and costimulatory molecules and
cytokines [23, 54, 55]. In this model, T-cells that receive
a weak signal will be unfit to diﬀerentiate and will rapidly
die [56]. An intermediate signal or a strong signal that
is followed by the clearance of antigen will result in the
development of fit memory cells which can eventually give
rise to precursors for rapid eﬀector cells generation upon
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Figure 2: Model of CD8 T-cell diﬀerentiation. (a) The highly diverse naive T-cell compartment contains T-cell clonotypes of very low
frequency (represented by one color), and null expression of eﬀector mediators but high potential for proliferation in response to antigen.
Following encounter with cognate antigen, CD8 T-cells are activated and begin a process of cellular diﬀerentiation characterized by a gradient
of early- and late-diﬀerentiated cellular states, that can be described by changes within four major parameters as depicted by dark grey blocks.
As a result of the massive cellular proliferation that ensues activation, there is an increase in the frequency of T-cells and a restriction in the
TCR diversity, since the pool of primed diﬀerentiated T-cells is composed of a small number of clonally expanded T-cells (blue, white, yellow,
and orange T-cells). Concomitantly, there is a decrease in proliferative potential from naive and early diﬀerentiated T-cell subsets towards
highly diﬀerentiated subsets. Moreover the accumulation of eﬀector functions (high production of eﬀector molecules, small black dots) in
these expanded populations of T-cells defines further maturation of diﬀerentiated T-cells. (b) The degree of diﬀerentiation of T-cells along
this spectrum has been shown to vary with antigen specificity. As such, the antigen-specific responses against influenza virus and against
persistent EBV and CMV viruses are compared with the tumor-specific response against the Melan-A antigen, while taking into account
the four parameters described in (a). EBV-specific cells are more diﬀerentiated than influenza-specific cells but less so than CMV-specific
cells which are composed primarily of highly diﬀerentiated CD8 T-cells. While both early and late diﬀerentiated subsets have also been
identified in Melan-A specific responses, their proportions are highly variable between diﬀerent patients following vaccination. In addition,
tumor-specific responses contain a much lower fraction of highly diﬀerentiated EMRA (eﬀector memory CD45RA+) cells compared with
viral-specific responses.
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antigen restimulation. When T-cells receive a strong signal,
they diﬀerentiate towards eﬀectors.
Thus, the presence and concentration of antigen would
be one of the main factors determining at what point
along this diﬀerentiation spectrum, each memory response
would be found. In other words, the relative proportions of
“memory-like” T-cell-subsets compared with the “eﬀector-
like” T-cell subsets would account for the observed diﬀer-
ences between various immune responses. Specifically, in
the presence of persistent antigen, EBV-specific memory
cells will be driven towards an eﬀector memory pheno-
type. Contrarily, several weeks or months after clearance
of pathogens causing short-term acute infections, that is,
in absence of antigen, the central memory compartment
would be dominant, while a lower fraction of T-cells would
exhibit an eﬀector memory phenotype. We also propose
that early (memory-like) and late diﬀerentiated (eﬀector-
like) cells serve important but distinct purposes to the
overall antigen-specific immune response and in providing
protection against diﬀerent viruses. Such observations are
in line with those made in the mouse model (reviewed in
[40]), as it was shown that while immediate protection is
better provided by diﬀerentiated eﬀector-type T-cells present
in peripheral tissues [57], early diﬀerentiated (TCM-like)
cells are most potent at protecting against systemic infection
with lymphocytic choriomeningitis virus and respiratory
challenge infections [57–59].
2.4. Recently Improved Strategies to Multiparameter Flow-
Cytometry Analysis. The ex vivo characterization of T-cells
is limited to T-cell populations with a frequency higher
than 0.01% among total CD8 T-cells [3, 4]. This is more
problematic for T-cell specific responses of rather low
frequencies such as those generated against tumor antigens,
in contrast to the relatively frequent viral specific T-cell
responses. To address such problems, two groups have
recently developed techniques for simultaneous analysis
of T-cells with multiple diﬀerent antigen specificity. The
first consists in the combination of 4 fluorochromes for
each T-cell specificity instead of a single one, allowing the
detection of 15 diﬀerent specificities in parallel [60]. The
other strategy is to increase the number of peptide-MHC
multimers labeled with a two-dimensional combination of
fluorochromes using six diﬀerent quantum dots (QD565,
QD585, QD605, QD655,QD705, and QD800) and the two
most intense fluorochromes PE and APC, which allows the
visualization of T-cells with up to 28 diﬀerent specificities
[61]. While both strategies make it possible to simultane-
ously analyze numerous antigen-specific responses in a single
step, they require careful setup of experimental controls.
Furthermore, these approaches are currently limited on one
hand by the development and application of sophisticated
reagents and on the other by the thorough analysis of
the data. Nevertheless, aside from decreasing the time of
the experimental procedure, one of the most important
advantages is that they allow the investigator to save precious
material from patients and donors, since the sample does not
have to be subdivided for multiple separate analyses [61].
The development of MHC class II multimers has been
much less successful compared with MHC class I multimers
due to several reasons. First, human MHC class II molecules
are highly polymorphic. Second, peptide binding aﬃnity is
generally lower for class II as opposed to class I molecules,
which is particularly evident for peptides derived from
tumors. One of the most successful strategies has proven to
be the initial production of HLA-DR molecules loaded with
a “placeholder” peptide followed by a peptide exchange step
using the peptide of interest. The eﬃcient replacement by
the peptide of interest remains one of the major limitations.
Recently, Ayyoub and colleagues reported DR52b/NY-ESO-
1 multimers using the strategy of His-tagged peptides
that allows isolation of folded MHC/peptide monomers by
aﬃnity purification before tetramerization [62]. Using these
molecules, they could detect ex vivo CD4 T-cell responses to
the NY-ESO-1 peptide in patients undergoing a vaccination
trial with recombinant NY-ESO-1 protein, Montanide ISA
51 (Seppic, France), and CpG ODN 7909 (Pfizer, USA).
The application of this strategy to other tumor- and self-
antigen-derived peptides may significantly accelerate the
development of reliable MHC class II multimers to monitor
antigen-specific CD4 T-cells.
2.5. Advantages and Limitations of the Multiparameter Flow
Cytometry Analysis. The major advantage of the multipa-
rameter flow-cytometric analysis is that it allows to ex vivo
visualize the antigen-specific pool of lymphocytes and to
divide it into numerous subpopulations. As discussed above,
antigen-experienced T lymphocytes are highly heteroge-
neous and are composed of a wide range of discrete subsets.
It is thus of high importance to elucidate the roles of these
diﬀerent subsets and to identify how they are regulated. In
that regard, in vivo/ex vivo analyses remain the gold standard,
and flow cytometry represents an instrumental technology
to study antigen-specific T-cell biology ex vivo. Moreover,
diﬀerences between various T-cell populations within the
same response can only be revealed in such studies. On the
contrary, the phenotypic analysis of a T-cell response as a
whole can lead to false conclusions and biases induced by
the predominant subset, while missing the presence of a less
frequent yet biologically important population. Multiparam-
eter flow cytometry technology allows the parallel detection
of multiple activation markers, such as the expression of
cytokines and chemokines by specific populations of cells
allowing the fine characterization of particular profiles.
Thereby it is possible to determine which parameters define
distinct functional subsets in diﬀerent antigen-specific T-cell
contexts. For instance, Makedonas and colleagues recently
showed that a polyfunctional response led by IL-2 upregula-
tion was necessary for the control of EBV and the clearance of
influenza, while conversely a strong perforin production was
rather important in the clearance of CMV and adenovirus
infection [63]. Lastly the technology allows to sort each
of these populations of interest into various forms (tubes,
plates), cell numbers (single cells), and for diﬀerent purposes
(in vitro cloning, ex vivo functional assays, and molecular
assays) as will be discussed in the following sections.
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3. Assessing Functionality of Antigen-Specific
T Lymphocytes
It is evident that the analysis of phenotype of T lymphocytes
using multiparameter flow cytometry can reveal a high
degree of heterogeneity, especially among the antigen primed
T-cell population. However, one should not only judge a
book by its cover, not a T-cell solely on its phenotype since
a high degree of heterogeneity exists even for T lymphocytes
of similar phenotypes or alternatively, similar functions for
T lymphocytes of distinct phenotypes. Thus, characterizing
the functional capacities of each individual T lymphocyte
is crucial to the understanding of their roles in vivo and
to designing future strategies to enhance and prolong these
functions through therapeutic vaccination. This section will
discuss current methods to study T-cell function either
directly ex vivo or following expansion in vitro and outline
the lessons learned about the functionality of viral and
tumor-specific T lymphocytes.
3.1. Current Strategies for Measuring T Lymphocyte Function.
Helper CD4 T-cells have been shown to be important in the
generation of eﬃcient and long-lasting memory responses;
however, cytotoxic CD8 T-cells remain the key eﬀectors
in the fight against most viral infections and tumors. The
functionality of CD8 T-cells can be studied in vitro or ex vivo,
whereby three parameters are often measured: cytotoxicity,
cytokine secretion, and proliferation.
The first pathway of cytotoxicity involves the engage-
ment of death receptors (TNF-α and Fas/FasL). The flow-
cytometric analysis of the expression of these receptors by
various T-cell subsets is possible; however, current in vitro
assays are not suﬃciently sensitive to correlate this with
diﬀerences in cytotoxic capacities by the same cells (reviewed
in [41]). The second pathway employed by CD8 T-cells is the
granzyme-perforin-dependent cytotoxicity. This is a highly
complex mechanism, which can be very diﬃcult to assess
using currently available approaches and extrapolated to the
true capacities of a T-cell in vivo. Specifically, the cytotoxic
potential of a T-cell in vivo will depend upon several factors,
such as the level of constitutive expression of granzyme
and perforin and storage into lytic organelles, the quantity
released following activation, and the rate of regeneration
of these molecules. These parameters may already diﬀer
significantly from cell to cell in vivo and may be further
altered following in vitro stimulation [41].
Nevertheless, numerous assays exist to study CD8 T-
cell cytolysis, the first being the degree of target cell death
induced by CD8 T-cells in an antigen-specific manner. In
vitro generated clones expanded in medium supplemented
with human serum and recombinant human IL-2 are
commonly used in such assays. One of the major advantages
of this approach is that the periodic restimulation of these
clones using phytohemagglutinin (PHA) and irradiated
allogeneic PBMC as feeder cells allows the generation of
a large number of cells and for extended periods of time.
This opens the possibility for experiments to be repeated,
as well as the simultaneous testing of several conditions
(antigenic peptide concentrations, eﬀector to target ratios).
The classical method of determining the in vitro lytic activity
of antigen-specific T-cell clones is through the 4 h 51Cr
release assays using antigenic peptide-pulsed T2 target cells
(HLA-A2+/TAP−/−) [64]. In the case of tumor-reactive T-
cells, melanoma tumor cell lines such as Me 275 and Me 290
(HLA-A2+/Melan-A+) and NA8-MEL (HLA-A2+/Melan-
A−) can also be used as target cells in the presence or absence
of exogenousMelan-A peptide [8]. The percentage of specific
lysis is then calculated in terms of the observed level of 51Cr
released compared with the spontaneous and total possible
release by the target cells. To quantify the eﬃciency of T-
cell—target cell recognition, results can be expressed in terms
of the amount of peptide required to reach 50% of the
maximal lysis (EC50). Alternatively the lytic activity of a
T-cell can be measured in a CD8 coreceptor independent
setting, specifically using C1R target cells transfected with
mutant HLA-A2 molecules that abrogate the docking on the
CD8 molecule [43, 65]. When these results are compared
with the level of lysis using targets expressing HLA-A2 wild
type, such assays allow the determination of the degree of
CD8 dependency, which can in turn be an indicator of
the level of binding avidity of the TCR for the peptide-
MHC molecule. While the 51Cr-release assay has several
practical advantages, it is not the most sensitive approach to
detect small diﬀerences in lytic abilities of diﬀerent clones,
particularly since the prior in vitro expansion of T-cells may
have dramatically altered their intrinsic cytotoxic machinery.
The alternative approach to study cell-mediated cytotox-
icity is through the multiparameter flow cytometry analysis
of markers associated with cellular death by the target
cell or with the cytolytic potential of the eﬀector T-cell.
The most popular approaches for the former are based on
the detection of caspase activation, annexin V binding to
apoptotic cells, and uptake of propidium iodine (PI) or 7-
amino-actinomycin D (7-AAD) by dead or dying target cells
(reviewed in [66]). On the other hand, the most commonly
used markers to detect potential killer T-cells versus non
killers are granzymes A, B, and perforin. To overcome the
constraint of having to fix the cells to allow intracellular
staining of these proteins, Betts et al. described a novel
strategy allowing the visualization of antigen-specific T-cells
expressing the cell surface CD107 degranulationmarker [67].
Accumulating evidence now shows that the expression of
CD107 by CD8 T-cells correlates well with their cytotoxic
potential and as a result CD107 is becoming routinely used in
clinical trial monitoring alongside markers of activation and
subset classification (discussed in [66]).
The Live Count Assay (LCA) was first described by
Deveˆvre et al. It combines several much-needed parameters
in T-cell functionality measurements. The LCA is a highly
sensitive, ex vivo method of analyzing low numbers of
antigen-specific T-cells for their cytolytic potential. Briefly
a 1 : 1 mixture of specific and control target cells labeled
with CMTMR is added to fluorescently sorted antigen-
specific CD8+ T-cells and incubated for 4 h in the pres-
ence of degranulation marker CD107a- and CD8-specific
mAbs. Samples are harvested, resuspended in staining buﬀer
containing DAPI and analyzed by flow-cytometry [68].
The optimization of the existing LCA protocol in order to
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ensure minimal sample consumption during fluorescence
sorting process is ongoing (Mahnke, Devevre, Speiser et al.;
manuscript in submission).
Experimental approaches, which allow the determination
of T-cell function along with T-cell quantification, continue
to be of high interest. For instance the ELISpot assay allows
the detection of T-cells having the capacity to produce IFN-
γ, a major cytokine secreted by CD8 T-cells and having
important actions in increasing CTL-mediated cytotoxicity.
The high sensitivity of this method makes it suitable for ex
vivo analyses of populations with low frequencies of antigen-
specific T-cells and of precious samples (PBMC, TIL, TILN).
Moreover it has been used for the characterization of fine
antigen-specificity and cross-reactivity on Melan-A-specific
T-cell clones [69] using a library of peptides predicted to
be potentially cross-reactive with the Melan-A peptide [70].
The authors showed that increased diﬀerentiation of derived
clones was associated with a decrease in TCR cross-reactivity
and an increased specificity against the native Melan-A
peptide [69].
The simultaneous detection of multiple cytokines using
approaches such as the cytometric bead array (CBA from
BD) or Luminex has significantly advanced the field
beyond the commonly used ELISA technique. While these
approaches are highly sensitive in detecting low amounts
of expressed cytokines, they require prior stimulation using
specific peptides and stimulating cells (DC or tumor cells).
Alternatively the intracellular cytokine staining (ICS) allows
the detection of cytokines expressed ex vivo by T-cells
and their subsets. The major drawback of the ICS is
that it requires fixation of the cells, meaning that viable
cells expressing a cytokine of interest cannot be isolated
and placed in culture to further determine its functional
properties. Nevertheless this flow cytometry-based technique
allows the simultaneous analysis of other intracellularly
and extracellularly expressed markers, which has recently
improved our understanding of the polyfunctionality of T-
cells. Specifically, recent data suggest that cells capable of
secreting multiple cytokines may play important roles in
the control of HIV infection, since an immune response
comprising such multifunctional cells was more frequently
observed in individuals who maintained a low level of the
virus and normal levels of the CD4+ T-cells for many years
(reviewed in [41]).
Last but not least, a proliferative potential of fully
functional cytotoxic T-cells is an equally important param-
eter to an eﬃcient immune response. As with many other
methods used to study functionality, the limitations of
some of the approaches used to study proliferation (BrdU
staining, CFSE dilution) involve an in vitro stimulation step
prior to the analysis. These assays can be informative in
making the distinction between cells with a high capacity for
proliferation such as central memory cells versus cells with
a lower capacity like highly diﬀerentiated cells, but may be
less sensitive to small diﬀerences between more functionally
similar subsets. Furthermore, a more accurate estimate of
the in vivo proliferative potential and history of a T-cell may
be provided by ex vivo strategies. Currently it is possible
to determine proliferative activity using Ki67 staining of
T-cells ex vivo, although this is also limited by an inability
to keep such cells viable for additional tests. The degree
of telomere shortening is another parameter, which can
provide information about the extent of in vivo proliferation
of a T-cell. Two of the most precise techniques currently
used to measure telomere length are flow-FISH, based on
the hybridization of telomere repeats using fluorescently
labeled probes [71, 72], and STELA (single telomere length
analysis) [73], a PCR-based technique of amplification of
telomeric and subtelomeric regions in individual chromo-
somes. Future studies are thus also needed to get a more
precise measurement of telomere length in small number
of cells, and even single cells. However, since telomere
dynamics does not seem to provide the only explanation
for the persistence of T-cell clonotypes (discussed in [74]),
other mechanisms of long-term survival in vivo should
be investigated. Specifically, the roles of IL-7 and IL-15
survival cytokines should be further investigated in various
T-cell populations across the diﬀerentiation spectrum, as are
molecules involved in increased survival and resistance to
apoptosis such as Bcl2. Finally, the replicative history of T
lymphocytes can also be investigated by quantifying their
content of TRECs, which are stable DNA episomes formed
during TCR-α rearrangement and are diluted out with each
cell division [75].
3.2. Future Targets for the Study of T Lymphocyte Functionality.
The fast advancing field of multiparameter flow cytometry
will continue to open many opportunities for the analysis of
the functional profiles of phenotypically distinct subsets of
antigen-specific T-cells in an ex vivo fashion. It is now even
possible to observe the events of the downstream signaling
cascades to the T-cell receptor or chemokine receptors at
the single cell level. For example, the level of Phospho-
Stat1 (pY701) and phospho-Stat5 (pY694) can be observed
after 15-minute stimulation with either interferon alpha and
gamma or IL-2/IL-15 on tumor antigen-specific CD8 T-
cells [76]. In addition one of the downstream events of T-
cell activation via the T-cell receptor is the phosphorylation
of ERK1/2 (pYr202/pY204). Contact of antigen-specific
peptide-pulsed antigen-presenting cells (APCs) leads to the
phosphorylation of ERK1/2 which can be detected as a
shift of the activated antigen-specific T-cells compared to
unstimulated control cells [77]. Another parameter which
can be useful in obtaining information about the capacity
of tumor antigen-specific T-cells to react to an appropriate
signal is the expression of the CD3zeta chain by intracellular
staining which can be compared with the level expressed by
total CD8 T-cells and viral antigen-specific T-cells [78, 79].
Importantly, additional markers allowing to select viable T-
cells for further ex vivo cellular and molecular assays of T
lymphocyte functionality are needed in the future, in order
to enhance our understanding of the functional properties
that correlate with immune protection.
3.3. The Functional Capacities of Tumor Reactive T Lympho-
cytes. It is now well established that an eﬃcient antigen-
specific CD8 T-cell response is one characterized by eﬀector
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cells with a strong ability to lyse antigen-specific target cells.
This is highly important in viral disease, both for acute (e.g.,
influenza) as well as for chronic or persistent (e.g., herpes
viruses) infections. It is now commonly accepted that T-
cells specific for foreign (e.g., viral) antigens can give rise
to strong protective immune responses, whereas self/tumor
antigen-specific T-cells are thought to be less eﬃcient.
Therefore, it is of great importance to study the functional
capacity, in particular the multifunctionality, of tumor-
reactive T lymphocytes before and following therapeutic
vaccination (Figure 1). We previously described a study on
the functional and proliferative potential of a dominant CD8
T-cell response directed against NY-ESO-1 [48]. We could
identify two functionally distinct populations of tumor-
specific T-cells. The major population making up to 90%
of the cells (EM28neg) displayed the hallmarks of highly
diﬀerentiated and active eﬀector T-cells. These cells were
able to mediate eﬃcient ex vivo killing, produced IFN-
γ, and still retained proliferative capacity upon antigenic
stimulation, while up-regulating NK-like receptors such as
CD57, CD94 as well as PD-1, an inhibitory receptor. The
other relatively minor population (EM28pos), representing
between 5 to 10% of NY-ESO-1 reactive CD8 T-cells, was also
diﬀerentiated with features consistent with a resting memory
state (CD28+CD27+CD127+PD-1−), suggesting that they
may serve to maintain eﬀector cells [48]. These findings are
in line with another study, in which we identified a single
naturally primed T-cell clone that dominated the CD8 T-
cell response to the Melan-A/MART-1 antigen [45]. The
dominant clone expressed a high avidity TCR to cognate
tumor antigen, eﬃciently killed tumor cells, and prevailed
in the diﬀerentiated eﬀector memory (EM28neg) T-cell com-
partment. Other outstanding properties of this monoclonal
T-cell population were the in vivo high frequencies, long-
term persistence (>3.5 years), and eﬃcient homing to
metastases. Remarkably, during concomitant vaccination,
we observed progressive enhancement of eﬀector attributes,
thus showing that repeated peptide vaccination together
with IFA and CpG allows the induction of functionally
competent tumor-reactive T-cells [45]. More recently, we
took advantage of CpG oligodeoxynucleotides as a powerful
vaccine adjuvant to induce and characterize T-cell responses
upon vaccination with the natural Melan-A (EAAGIGILTV,
“EAA”) versus the analog Melan-A (ELAGIGILTV, “ELA”)
peptide antigen [14]. Compared with vaccination with
analog peptide, natural peptide-induced T-cell frequencies
were approximately twofold lower. However, T-cells showed
superior tumor reactivity because of (i) increased functional
avidity for natural antigen and (ii) enhancement of T-cell
activation and eﬀector function. Altogether, such studies
are essential to characterize the functional requirements
of tumor-specific T-cells upon vaccination. Moreover, they
support further development of vaccine formulations with
CpG and peptides in large-scale phase III trials.
It is essential that eﬀector-type T-cells, once activated
upon antigenic challenge, reach (“home to”) aﬀected tissues
for the elimination of infected or malignant cells. In human
cancers, current knowledge of the in vivo functions of tumor-
specific T-cells has been until recently restricted to peripheral
blood T-cells; however, studies on the functional activities
of such cells at the site of tumor lesions are becoming
possible and popular [80, 81]. At present, several reports
have described that while circulating Melan-A-specific CD8
T-cells exhibited characteristics in common with the eﬀector
T-cells, tumor-specific T-cells that reside in metastatic lymph
nodes and soft tissue and visceral metastases appeared
functionally attenuated as compared with circulating T-cells,
despite their accumulation at high frequencies in tumor
lesions [50, 82, 83]. This coincided with a significant increase
of FoxP3+ regulatory T-cell activity within the tumor [50,
84]. Moreover, Melan-A-specific T-cells failed to produce
IFNγ in both metastatic lymph nodes and nonlymphoid
tissue metastases, but this defect was reversible in the
presence of low dose IL-2/IL-7 cytokines in vitro [82], in
line with gene expression profiling revealing downregulation
of the interferon signaling pathway in T-cells from patients
withmetastatic melanoma [76]. Finally, Beyer and colleagues
recently described that these nontumor reactive CD8 T-
cells are characterized by a molecular program associated
with the hallmarks of “division arrest anergy” [85]. There is
still only limited data available regarding T-cell clonotypes,
likely because this approach is labor intensive (see coming
sections). Yet, clonotypic analyses provide promising results,
mostly because T-cell clonotypes can be followed in a
straightforward manner at any time and body location using
the TCR as a clonotypic marker (reviewed in [74, 86]).
For instance, further comparisons of the phenotype and
T-cell clonotype composition between viral- and tumor-
specific responses should be carried out between the blood
and tumor site in patients where samples are available.
Such analyses could extent previous studies while focusing
on changes in the proportions of T-cell subsets and the
potential selection of TCR clonotypes following migration to
metastatic lesions [48]. This would also allow determining
whether the expression of the tumor antigen at these
sites negatively influences selection of tumor-specific TCR
clonotypes compared with “bystander” viral-specific T-cells,
which are not stimulated locally by their specific antigen.
4. Each T-Cell Is Unique: Gene Expression
Profiling of Single Cells
An alternative strategy of avoiding the need for in vitro
cultured T-cell clones is to analyze the gene-expression
profile of ex vivo sorted cells. The standard microarray
approach can be used for gene-expression profiling of T-cells
of particular phenotypes; however, it is limited to the study
of at least 100–1000 cells [87]. Nevertheless, the technique
has evolved over the years to allow gene-expression profiling
of coding and noncoding regions of the genome, which still
makes it the goldstandard approach for identifying novel
diﬀerentially expressed genes. Once these genes of interest
have been identified, the ultimate goal is to perform detailed
analyses on a limited number of antigen-specific T-cells and
subpopulations. For this purpose, our group has developed
a strategy consisting of cell lysis and cDNA synthesis in
a single-step procedure, followed by a modified RT-PCR
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protocol that relies on the detection of specific cDNAs
after global amplification of expressed mRNAs [32, 88].
This method yields suﬃcient cDNA from as few as five
cells. Thus, a major advantage is that it allows the analysis
of gene expression and TCR repertoire analysis in small-
purified subpopulations of antigen-specific cells even when
a limited amount of material is available. Furthermore, since
the global amplification is not selective and the amplified
cDNA remains stable for long periods of time at −80◦C,
this approach allows the amplification of genes of interest
even at later time-points. We have previously employed this
strategy to study the heterogeneity of CD8 T subpopulations.
Five-cell aliquots isolated following multiparameter flow
cytometric analysis were subjected to global amplification
of cDNA, followed by the specific amplification by PCR
of genes known to be diﬀerentially expressed at distinct
stages of cellular diﬀerentiation (Figure 1). As such, the
expression patterns of the CD27 costimulatory receptor,
the IL-7Rα, and the expression of the cytotoxic molecules
granzyme B and perforin have permitted the identification
of a number of T-cell subpopulations, including pre-eﬀector
and eﬀector memory subsets [32, 34, 88], as well as the fine
characterization of tumor-specific CD8 T-cell responses in
the context of therapeutic peptide vaccination (see [45, 48];
Rufer, Speiser et al., unpublished observations).
4.1. Towards Single Cell Profiling. During T-cell diﬀerentia-
tion, the stochastic events becomemore prominent involving
a set of modifications of multiple gene expressions inducing
subtle or dramatic changes in the cell. Such changes incur
variability among the antigen-primed T-cell populations and
even among “naive” cells. CD8 T lymphocytes are a well-
defined example of such a phenomenon. Such inevitable
heterogeneity in biological systems emphasizes the need to
determine this variation by analyzing single cells. Recently,
we have optimized the above-described strategy of global
cDNA amplification at the single cell level. This provides
us with the added advantage of being able to determine
the gene-expression profile of a single T-cell clone defined
by its unique CDR3 sequence (i.e., a TCR clonotype).
One drawback of this method is that low frequency TCR
clonotypes require the isolation of numerous single cell
samples for its detection. Nevertheless, it is highly powerful
in that one can follow single TCR clonotypes over time before
and after vaccination and compare their gene-expression
profiles between (i) vaccination protocols, (ii) patients, (iii)
T-cell subpopulations, (iv) anatomical localizations, and (v)
over time. Furthermore, one can correlate the information
gathered on the ex vivo gene-expression profile of a TCR
clonotype of interest, with the functionality of a T-cell clone
bearing the same unique receptor in vitro. Currently, our
group is interested in understanding how the diﬀerentiation
of melanoma-specific T-cells is aﬀected by factors such as
the type and dose of antigenic peptide used for vaccinating
patients. The profiles of these cells will be subsequently
compared against EBV- or CMV-specific T-cells, of which we
know that they ensure eﬃcient viral control in vivo, in spite of
diﬀerences in phenotype, functionality, and TCR clonotype
composition [43].
The cDNA global amplification technique provides infor-
mation on the expression of genes at themRNA level, and not
at the protein level. However, the combination of the single
cell gene-expression profiling and the multiparameter flow
cytometry analysis using antibodies against the respective
proteins can overcome this limitation. The disadvantage
of the nonspecific amplification technique is that it is not
quantitative, since the main principle of the technique relies
on the nonspecific amplification of all expressed mRNAs
present in the cell. Furthermore, particularly at the single
cell level, this technique remains limited to the study of
genes expressed at moderate and high levels within the
cell, since genes expressed at very low levels may not be
detected even following the global amplification procedure.
Thus, overcoming this limitation may be a challenging
task, although working with cDNA material of high quality
and purity is indispensable. This requires a very clean and
sterile working environment. All steps preceding the global
amplification must be performed in an RNAse and DNAse
free environment, free from potential sources of contaminant
material.
4.2. Single Cell Profiling Strategies by Other Groups. Although
for some time the direct quantification of gene expression
a single cell was considered impossible since the amount of
mRNA extracted from a cell is minute, there is now strong
evidence of its feasibility, allowing eﬃcient and reliable
assessment of gene expression of individual cells [89–91].
Peixoto and colleagues reported of a method wherein they
successfully quantified the expression of 20 diﬀerent genes
simultaneously from a single cell using reverse transcription
of single cell mRNA with 3′-specific primer of each gene
of interest [89, 90]. This cDNA was then amplified by a
multiplex PCR of all 20 gene-specific 3′ and 5′ primers,
followed by a seminested real-time PCR for each individual
gene. Using this approach, Monteiro et al. investigated the
heterogeneity of the CD8pos T-cell compartment, by first
identifying several T-cell subpopulations using four extra-
cellular markers (CCR7, CD45RA, CD27, CD28), followed
by the analysis of mRNAs coding for chemokines, cytotoxic
molecules, or eﬀector cytokines expressed in single cells
from these subsets [33]. This in-depth single cell profiling
could demonstrate that certain T-cell subsets belonging to
the memory compartment such as the EM T-cells expressing
CD27 at high levels could exhibit similar functionality
profiles as naive T-cells. Additionally CCR7− cells expressing
both CD27 and CD28 showed similar profiles as central
memory cells, in line with our own observations [34].
On the other hand, highly diﬀerentiated CD27 and CD28
double negative cells were highly similar in their gene-
expression profiles regardless of CD45RA expression. The
results obtained by this quantitative single-cell multiplex RT-
PCR approach clearly depicted a high degree of heterogeneity
with each cellular subset displaying characteristic patterns of
gene expression, pointing to a hierarchical order of T-cell
diﬀerentiation stages among the antigen-experienced cells
[33]. Furthermore, even for individual cells belonging to the
same subset, the gene-expression profiles showed variability,
outlining the necessity to study multiple parameters in
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order to characterize the uniqueness of each single T-cell.
The main drawback of this strategy is that it can quantify
multiplex PCR applied to only 20 preselected genes of
interest expressed in a cell and thus fails to amplify high
amounts of cDNA that can eventually be used to individually
quantify any gene of interest, for example, TCR BV clonotype
expression.
Since the study of single T lymphocytes remains one of
the ultimate goals, other groups have developed approaches
for this highly specific type of analysis. For instance, the
Ampligrid platform by Beckman Coulter can be employed
to sort single cells on unique hydrophilic/hydrophobic
structured glass slides containing individual wells, which can
then be directly used for PCR amplification in a very small
volume allowing higher sensitivity. The chemically modified
glass slide wells can be used as single reaction centers for
cell growth and PCR all in one place [92] in which cells are
stimulated, washed, and dried in situ, avoiding numerous
handling steps and cellular stress [93]. This platform has
already been used for the genetic analysis of circulating
tumor cells in small-scale clinical trials [94] and is particu-
larly advantageous for multiplex real-time PCR [95], robotic
micromanipulations, and laser microdissection [96]. This
method has a high sensitivity with a detection level threshold
of 32 pg of purified DNA, allowing the minisequencing of
mitochondrial DNA down to a single lymphocyte [97]. Yet,
it also requires further optimization at the single cell level,
since the eﬃciency may sometimes vary drastically from 20
to 80% [98] and a second seminested amplification may still
be necessary for certain genes [99]. Furthermore, the optimal
handling of minute volumes of numerous single cell samples
should require robotized approaches.
5. T-Cell Receptor (TCR) Repertoire and
TCR Clonotype Analysis
A better understanding of the structural principles that
govern TCR-pMHC binding is essential to promote research
and clinical applications. The quality of TCRs recruited
during disease, or by vaccination, dominantly influences
the potency of immune responses. To improve therapeutic
immune interventions, TCRs need to be fully characterized,
and the mechanisms for their recruitment and functionmust
be elucidated. Results from such studies have a strong impact
on the design of antigens for vaccination as well as on the
choice of optimal TCRs for adoptive T-cell therapy, with or
without TCR gene transfer.
Several strategies exist to assess the TCR repertoire
diversity and clonal composition of various pools of antigen-
specific T-cells. A straightforward approach is to combine
the staining with peptide-MHC multimers with a panel of
monoclonal antibodies (mAb) directed against the variable
region of the TCR β chain (anti-BV). While this approach
allows the direct and quantitative assessment of BV usage
by tumor- and viral-specific CD8 T lymphocytes, it does
not reveal whether the BV-restricted T-cell response analyzed
is of monoclonal or of polyclonal nature (reviewed in
[86]). The immunoscope or CDR3 spectratyping technique
measures the size heterogeneity of the CDR3 region of the
TCR and provides a powerful tool to characterize in-depth
the level of the TCR repertoire complexity (reviewed in [86,
100]). Since most human TRBV segments can be amplified
using 22 BV-specific primers as previously reported [101],
fluorescently labeled primers specific for each TRBV gene
segment and a primer specific for the constant region of
the β chain of the TCR are used to amplify specifically the
expressed CDR3β gene segment. The labeled PCR products
are then run on an automated sequencer in the presence
of fluorescent size markers to obtain the precise size of the
CDR3 region (reviewed in [86]). Expansion of particular
antigen-specific T-cell clonotypes is visualized as single
dominant PCR peaks of a given size and PCR products
are sequenced to obtain the nucleotide sequence of the
CDR3 region. Analyses are then focused on determining the
dominant clonotypes (defined as the presence of the same
TCR BV-CDR3-BJ sequence in two separate subsets or time-
points). They can be further divided into highly dominant
or subdominant clonotypes, based on their frequencies in
an immune response. Subsequently a comparison of the
frequencies of a given clonotype can be made between
diﬀerent T-cell subsets, between diﬀerent time-points, and
even among diﬀerent individuals (Figure 1).
5.1. Advantages and Limitations of the Spectratyping/Clonoty-
ping Technique. Today, the spectratyping/clonotyping appr-
oach has proven to be a strong analytical technique, allowing
both detecting oligoclonal T-cell expansion ex vivo and
assessing the presence and frequencies of dominant T-cell
clonotypes among virus- and tumor-specific CD8 T-cell
subpopulations [43–45, 48, 49, 51, 52]. Yet, this approach has
some limitations. The first one stems from the cross reactivity
of the diﬀerent TRBV oligonucleotide primers used. Due
to the homology between several TRBV gene segments and
the existence of several subtypes for numerous TRBV gene
families (e.g., 14 variations of TRBV13 and 25 for TRBV6),
the primer sequences utilized have a certain degree of cross-
reactivity. In fact, the likelihood of unspecific recognition can
be theoretically calculated for each primer set against all BV
gene segments. Nevertheless, performing individual TRBV
PCR (in contrast to multiplexing), sequencing of doubt-
ful PCR amplicons, and careful analysis of the upstream
sequences allows to accurately determine whether the PCR
product corresponds to the correct amplified TCR BV family
or is the result of cross-reactivity against another BV family.
Another limitation is that there are instances where the
TCR of one sample or clone cannot be identified despite
repeated eﬀorts. The more likely reason for this observation
is that the 22 pairs of primers used detect an estimated
>90% of all known TRBV families and subfamilies. Thus,
although detection of the majority of all TRBV subfamilies is
theoretically ensured, some TCR clonotypes among antigen-
specific T-cell responses could express rare and particular BV
segments and thus remain undetected by the spectratyping
technique (own unpublished observations).
The spectratyping approach of analyzing T-cell clono-
type composition requires a high number of samples to be
sequenced. The strategy developed by our group involves
the analysis of CDR3 sizes among T-cells population as
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an early step, followed by the analysis of potential candi-
dates for dominant clonotypes. This reduces the number
of sequencing reactions of unique BV and unique CDR3
lengths. When the sequencing of several PCR products has
yielded the same TCR sequence for a given BV, clonotypic
primers can be designed to allow faster identification of these
TCR clonotypes among the remaining samples. The forward
and reverse clonotypic primers are designed to specifically
recognize the unique CDR3 sequence of each clonotype and
are used in combination with the BC primer, and BV primer
respectively. In certain instances, clonotypic primers cannot
be designed, because of lack of specificity or because CDR3β
sequences are too similar. This is the case for most EBV-
specific TCR clonotypes of the TRBV2 and TRBV4 families as
they share highly similar CDR3 sequence motifs, sometimes
diﬀering by only one amino acid, and in these situations, all
samples are being sequenced [43].
Finally, as the spectratyping technique is only semiquan-
titative, the amplification of cDNA from antigen-specific T-
cell poolsmight introduce biases, leading to the nondetection
of variations present within a particular CDR3β length
(reviewed in [102]). Sequencing of antigen-specific T-cells
at the single cell level should overcome most of these
restrictions [103–105]. This aspect as well as the limitation
in the determination of precise frequencies from individual
clonotypes has prompted us to recently redefine our spec-
tratyping/clonotyping approach towards the single cell level.
5.2. Clonotype Selection and Composition of Antigen-Specific
T Lymphocyte Subsets. It has been proposed that the large
heterogeneity that is observed among T-cell subsets may
be influenced by the clonotype composition found within
these subpopulations. Indeed, diﬀerent TCRs, which vary
in mechanism and strength of peptide-MHC binding, may
lead to distinct activation and diﬀerentiation. However, it
is evident that cellular heterogeneity exists even within the
same T-cell clonotype (reviewed in [106]), as demonstrated
in TCR-transgenic mice [106, 107], and in the elegant study
by Stemberger and coworkers [108], in which it was shown
that a single naive CD8 T-cell precursor can diﬀerentiate
into diﬀerent eﬀector and memory subsets. Studies of the
human TCR repertoire are somewhat conflicting, with some
groups reporting that eﬀector and memory are derived
from identical, naive precursor cells [109, 110], while others
suggest that they are recruited from distinct precursor cells
[111].
Our group recently performed an in-depth analysis of
the clonal TCR repertoire diversity and selection among
healthy donors infected with persistent herpes viruses [43]
or following influenza infection [44]. Sequencing of the
TCR beta chains showed that the clonal composition was
highly restricted for both influenza- and CMV-specific cells
(between 1–3 dominant clonotypes), whereas it was relatively
diverse for EBV-specific cells (on average 15 clonotypes).
Importantly, these analyses revealed for the first time in
a steady state of human T-cell memory that individual
clonotypes can diﬀerentiate and be maintained within both
the early- (memory) and late-diﬀerentiated (eﬀector) T-
cell subsets [44]. Data also indicate, in the EBV model,
that the early diﬀerentiated memory subset is the most
diverse and contains virtually all clonotypes found in
the highly diﬀerentiated eﬀector subset [43]. Yet, striking
diﬀerences in the patterns of dominance can be observed
among both subsets, since some clonotypes are selected with
diﬀerentiation while others are not. Remarkably, clonotype
selection and composition of EBV- and CMV-specific subsets
upon diﬀerentiation are highly preserved over time, with
the presence of the same dominant clonotypes at specific
diﬀerentiation stages over a period of 4 years. Altogether,
these observations demonstrate that T-cell clonotypes seg-
regate with diﬀerentiation, but the clonal composition once
established is kept constant for at least several years [43]
(Figure 3).
Therapeutic vaccines against cancer aim to induce
eﬀective immune responses similar to protective antiviral
responses. Previously, we showed that a potent vaccine
formulation composed of low doses of Melan-A/MART-
1 peptide, IFA, and low doses of CpG oligonucleotides
induced ex vivo detectable T-cell expansions in virtually
all melanoma patients reaching on average more than 1%
of specific CD8 T-cells [13, 14]. Extensive analyses of the
tumor-specific responses among peptide vaccinated patients
revealed that the Melan-A/MART-1-specific T-cell responses
were also relatively diverse comprising between 10 to 15
clonotypes, depending on individual patients (Rufer, Speiser
et al., unpublished observations). These data are consistent
with another report [49], in which we found that the number
of dominant NY-ESO-1-specific T-cell clonotypes among
patients was between 6 and 10 clonotypes (Figure 3). A
striking observation is that tumor-specific T-cell responses
can, in some rare patients, be dominated by single dominant
clones [45, 49]. Collectively, a general observation is that,
similarly to viral-specific T-cell responses, responses to
Melan-A and NY-ESO-1 epitopes are also caused by selection
and amplification of particular T-cell clonotypes, following
T-cell diﬀerentiation (Figure 3). Specifically, the majority
of the patients showed progressive TCR repertoire restric-
tions, from early diﬀerentiated to late diﬀerentiated T-cells,
indicating the occurrence of oligoclonal T-cell expansions
in the latter compartment. Thus, the EM28neg (“eﬀector-
like”) subset consists primarily of codominant T-cell clono-
types, whereas the EM28pos (“memory-like”) contains large
polyclonal TCR repertoires with the presence of numerous
nonclonotypic sequences (see [45, 48], Rufer, Speiser et
al., unpublished observations). Finally, most tumor-specific
clonotypes identified in the late diﬀerentiated EM28neg
subset were also found within the EM28pos T-cells, in
agreement with our recent observation made in CD8 T-cell
responses against influenza [44] and herpes viruses [43].
Altogether, these results provide further evidence for a linear
model of T-cell diﬀerentiation, in which a small number of
clonotypes are selected to diﬀerentiate from a larger pool
of less diﬀerentiated “memory” cells. Figure 3 summarizes
the TCR diversity observed for tumor-specific CD8 T-cell
responses compared with viral-specific responses. While
larger numbers of codominant clonotypes are found for
Melan-A/MART-1-specific T-cells, CMV responses involve
low numbers of clonotypes. Nevertheless in all instances a
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Figure 3: TCR repertoire restriction and TCR clonotype selection are driven by diﬀerentiation. Analysis of TCR repertoire diversity and
clonotype composition between tumor-specific responses (left side of the figure) and viral-specific responses (right side of the figure) suggest
that all antigen-specific T-cell responses undergo selection along with progressive cellular diﬀerentiation (top to bottom of figure). As such,
early diﬀerentiated subsets show a higher degree of clonal diversity relative to their more diﬀerentiated subsets. Nevertheless, dominant
clonotypes are also found in the former but make up significantly larger proportions of the more diﬀerentiated compartments (defined as
TCR clonotype selection) supporting a linear model of diﬀerentiation. In addition, viral-specific responses which are composed of highly
diﬀerentiated cells (EMRA T-cells) also show a higher degree of TCR repertoire restriction compared with tumor-specific responses, evident
not only in the late but also already in the early diﬀerentiated subsets (indicated by a decrease in numbers of BV families and numbers of
clonotypes from left to right). Each colored slice of pie represents a unique TCR clonotype, while the grey slices represent nondominant
TCRs, that is, the sequences identified only once within the antigen-specific TCR repertoire. Melan-A (ELAGIGILTV) and NY-ESO-1
(SLLMWITQC) peptide sequences are indicated for the tumor-specific responses; virus specific T-cells were analyzed for the epitope EBV
BMLF1280–288 (GLCTLVAML) and for the CMV epitope pp65495–503 (NLVPMVATV). All responses are HLA-A2 restricted. Preferential TRBV
family usage is depicted based on IMGT’s nomenclature [112].
clear selection is observed with T-cell diﬀerentiation, such
that only a small number of TCR clonotypes are found to
dominate the highly diﬀerentiated subsets.
5.3. Alternative Strategies to Study TCR Repertoire Diversity
and Composition of Antigen-Specific CD8 T-Cell Responses.
Koup, Douek, and coworkers have developed over the past
decade an alternative approach to address the complexity
of the TCR repertoires in several antigenic systems [113].
Its principle is based on the use of a template switch-
anchored RT-PCR with primers specific for the 3′ TCR
constant region to amplify all expressed TRBV or TRAV
gene products. Since no primers specific for the TRBV-
or TRAV-gene segment are applied, this strategy does not
introduce bias associated to particular Vβ or Vα families
(see the above discussion). The resulting PCR amplicons are
then ligated into a plasmid vector, and cloned and selected
colonies are sequenced. This powerful strategy allows the
analysis of TCRs at the single cell level and provides an
absolute frequency of particular CDR3β usage. One of the
major disadvantages of this technique is the relative high
cost associated with the need to sequence thousands of
individual CDR3 gene segments. Moreover, biases related
to the eﬃciency of the ligation and transformation of
bacterial cells may still be introduced. Finally, the design
of clonotypic primers specific to identified dominant T-cell
clones when combined to quantitative real-time PCR allows
the quantification of clonotypes at any given time-point
during longitudinal studies [113]. This approach has led
several research groups to achieve major advances in the fine
characterization of CD8 T-cell responses during SIV [114–
117], HIV [118–123], CMV and EBV [124, 125] infections as
well as in patients suﬀering from melanoma [126, 127] or of
hematological malignancies [128]. Describing in detail these
publications is beyond the scope of this paper and, therefore
we have chosen to discuss some aspects of this extensive work
that is more closely related to ours.
An important question concerns the frequency and the
functional properties of public versus private clonotypes
and the bona fide clinical benefit obtained after their in
vivo expansion following viral infection or therapeutic
vaccination. Public clonotypes are defined by the presence
of the same identical TRBV-CDR3-BJ and/or TRAV-CDR3-
AJ sequences found in two unrelated individuals or ani-
mals. Recently, Price et al. have described the protective
activity mediated by public Gag- specific TRBV clonotypes
in vaccine-induced SIV-specific CD8 T-cell responses, and
observed that the number of public clonotypes correlated
inversely with the virological outcome after SIV challenge
[114]. Compared to private vaccine-induced SIV-specific
Journal of Biomedicine and Biotechnology 15
T-cells, T-cell populations with public clonotypes exhibited
greater levels of cross-reactivity to epitope variants, thus
indicating the need to preserve some degree of cross-
reactivity to contain viral escape [114]. Similarly, public
TRBV sequences that are shared between HLA-matched
individuals have also been described within the TCR reper-
toire specific for viral epitopes that do not mutate as in
the case of EBV and CMV [43, 125, 129]. Venturi and
colleagues have proposed that the sharing of TCR-beta chain
between healthy individuals is strongly associated with TCR-
beta production frequency and that a process of convergent
recombination facilitates the more eﬃcient production of
those TRBV sequences [115, 130, 131].We recently identified
public TRBV sequences isolated from 15 melanoma patients,
and unlike viral-specific TCR repertoires, such public TRBVs
were primarily expressed by nondominant and infrequent
T-cell clonotypes [51]. This highly contrasted with private
CDR3β signatures frequently found in T-cell clonotypes
that dominated repertoires of individual patients. Clearly,
common TRBV motifs have been selected after vaccination
in diﬀerent patients, but at much lower frequency compared
to distinct and private TCR structures. Yet, both public and
private antigen-specific TCRs recognized tumor cells with
comparable avidities suggesting that neither had a clear func-
tional advantage [51]. Future directions involve understand-
ing the structural and biophysical impact of public and pri-
vate TCRs in the process of recognition of the pMHC com-
plex, T-cell activation, and subsequent T-cell functionality.
The characterization of T-cell clonotypes bearing partic-
ular TCR CDR3 motifs, of their frequencies in well-defined
phenotypic populations, as well as of their related cytolytic
functions has revealed the need to understand the basis of
the structure-function relationship of a given TCR to its
pMHC molecule. This requires detailed studies performed
at the molecular level of the TCR and the delineation of
multiple parameters involved in the TCR signaling (e.g., CD8
coreceptor), combined with the characterization of intrinsic
biophysical factors of the TCRmolecule (e.g., CDR structural
loops and binding kinetic rates). In that regard, the recent
crystal structure of the Melan-A-MHC-TCR complex by
Cole and colleagues brought important insights into the key
elements within the TRAV and TRBV gene segments that are
involved in the recognition of the Melan-A antigen [127].
They showed that only CDR1α, CDR3α, and CDR3β loops
make contacts with the antigen and propose that this unusual
pattern of antigen recognition may explain the unique
characteristics and extraordinary frequencies of CD8pos T-
cell responses to this epitope. Moreover, Asn92 is the only
residue from the CDR3α that interacts with the antigen
[127], and since it is commonly expressed by TRAV12-2
(or TCR Vα2.1) positive T-cell clonotypes [51], this finding
may provide some explanation for the preferential segment
usage of the TRAV12-2 in Melan-A-specific T-cell responses
[132, 133].
Peptide-based cancer vaccines are often prepared with
altered “analog” peptide antigens that have been opti-
mized for HLA class I binding, in order to enhance
their immunogenicity. An obvious but crucial point is
that structural modifications of peptides should not alter
TCRαβ repertoires or TCR binding properties, to ensure that
vaccination-primed T-cell clonotypes remain highly specific
for the natural antigen and eﬃciently recognize tumor
cells. Recently, we demonstrated fine specificity diﬀerences
and enhanced recognition of naturally presented antigen
by T-cells after vaccination with natural Melan-A/MART-
1 peptide as compared with analog peptide [14]. These
data highlight the importance of careful re-evaluation of
studies using analog antigens with regard to the risk of
activating T-cells with “imprecise” antigen specificity or low
TCR aﬃnity. We recently addressed the question whether the
observed fine peptide antigen specificity could be explained
by structurally diﬀerent TCRs recruited and promoted by
vaccination with natural versus analog Melan-A/MART-1
peptide. In this study [51], we compared the TCR primary
structures of 1489 HLA-A∗0201/Melan-A26–35 specific CD8
T-cells derived from patients after vaccination with the
natural or the analog peptide. Collectively, our data indicate
that T-cell repertoires generated against natural or analog
Melan-A peptide exhibited slightly diﬀerent but otherwise
structurally conserved TCR features, strongly suggesting that
the diﬀerences in binding aﬃnity/avidity of TCRs towards
pMHC observed between both cohorts of vaccinated patients
are caused by subtle structural TCR variations [51]. Very
recently, Cole and colleagues [126] evaluated the intrain-
dividual clonotypic responses to both analog and native
Melan-A peptide following in vitro peptide stimulation,
thus allowing comparison between samples derived from
the same naive T-cell pool. They found that despite a clear
bias towards particular TRBV gene usages and the presence
of the GXG public motif in the CDR3β loop, similarly to
previous reports [51, 134], the majority of the clonotypes
were nonoverlapping between the two TCR repertoires [126].
These data further illustrate (i) the importance to monitor
T-cell responses at the clonotype level and (ii) emphasize the
need to the careful evaluation of such heteroclitic peptide-
based immune interventions to ensure eﬃcacy in the clinic.
6. Applying Improved Knowledge to
Clinical Studies
Progress in basic immunology has led to a better under-
standing of immune protection against cancer. Although
there is still much more to learn, we now know how
to activate the immune system and which cellular and
molecular components are key for immune protection. The
knowledge is currently applied in clinical studies, with the
aim of introducing immunotherapy against solid cancers in
clinical routine in a few years from now (Figure 1).
The design of potent antitumor vaccines currently faces
several obstacles, which will need to be addressed in order
to improve their eﬃcacy. One of them is the choice of
optimal tumor antigens, as reviewed by Boon et al. [2].
For instance, mutated antigens, although unique to tumor
cells, may not be shared among diﬀerent individuals, thus
raising the problem of individualized versus universal tumor-
vaccines. In contrast, diﬀerentiation antigens (such asMelan-
A/MART-1) are expressed by tumors from many individuals.
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However, their expression in normal cells poses targeting
problems thus toxicity, and of breaking immune tolerance.
Since these concerns are found on opposite sides of the
balance, addressing both of them will prove diﬃcult. The
use of potent adjuvants may be successful in stimulating
immune responses at a cost of autoimmune eﬀects, as for
example observed in melanoma patients who developed
vitiligo following vaccination [135].
Recent technological advancements now allow dissect-
ing immune responses and compare the phenotypic and
functional characteristics of various antigen-specific T-cell
populations. An increased understanding of the genera-
tion and maintenance of memory T-cells in virus-specific
responses will also help to better determine T-cell correlates
of protection. This is important in the design of tumor-
specific vaccines, as well as in determining which T-cell
subset may be most optimal for adoptive cell transfer.
Furthermore, recent studies have shown that vaccination
with peptide analogues [14] with enhanced binding to MHC
may result in the selection of unfavorable T-cells [51, 126].
Therefore, the stability of the peptide-MHC complex should
always be taken into account when assessing aﬃnity and
avidity of TCR-mediated recognition.
Aside from the fact that tumor-/self-antigen-specific T-
cells are less frequent than T-cells specific for pathogens,
their capacity to recognize and interact with cognate antigen
bearing cells is inferior. This is at least in part explained by the
lower TCR aﬃnity, resulting in reduced functional avidity.
With a few exceptions, the so far best human cancer-specific
TCRs have been isolated from patients with extraordinary
strong spontaneous CD8 T-cell responses, often associated
with unusually favorable clinical histories [45, 48]. Inter-
estingly, T-cells isolated from metastases, particularly from
tumor infiltrated lymph nodes, usually bear better TCRs
than T-cells from peripheral blood, reflecting enrichment of
specific T-cells in the tumor microenvironment. Unfortu-
nately, TCRs isolated after vaccination with tumor antigens
are often of lower avidity [45, 136–138], indicating that
current generations of tumor vaccines are suboptimal for
the selection of the best T-cells. It may even be possible that
many of the TCRs isolated after immunotherapy have been
primed earlier and were thus not primed but only boosted
by the applied therapy. This issue needs to be clarified, for
a full characterization of vaccination driven selection of T-
cell clonotypes. It is necessary to improve vaccines in this
regard, for example, by reducing vaccine antigenicity (with
e.g., lower antigen doses or weaker antigens), or by limiting
antigen presentation to professional antigen-presenting cells.
However, it remains possible that patient’s tumor specific
TCR repertoires are fundamentally deficient. In this case,
gene therapy with improved TCRs may be a valid approach
(reviewed in [139]). Current and future developments in
this regard [140, 141] will show whether this is a critical
point. Finally, competent TCRs may exist in cancer patients
but T-cell precursor frequencies may be too low, limiting
the potential to generate strong and long-lasting T-cell
responses. If so, gene therapy with naturally occurring TCRs,
introduced in larger numbers of (naive) T-cells may be
beneficial for improved clinical outcome.
In this paper we have focused on CD8 T-cell responses,
which are important for cancer patients, since CD8 T cells
can counteract tumor progression. However, tumors and
their microenvironment include many more components.
Tumors have been described as “wounds that never heal,
that regularly reorganize their strategies for persistence and
progression. Instead of stopping the disease, some compo-
nents of the immune system can actually promote cancer, by
provoking chronic inflammation and elaborating factors that
may support tumor cell growth, survival, and angiogenesis.
Furthermore, established tumors use immune-regulatory
circuits to generate an immune-suppressive environment,
which can act as substantial barriers to protective T-cell
responses. Progress in our understanding of the molecular
mechanisms governing the interaction between tumors and
the immune system has been the basis for improvements
of cancer therapy (reviewed in [142]). In view of the
formidable challenge to fully understand the plethora of
processes employed by tumors, it is evident that further work
is needed to optimize cancer therapy, by targeting principal
mechanisms of malignant diseases.
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